Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Work
Year: 2016
Type: article
Abstract: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that ex... more
Source: New England Journal of Medicine
Institutions LungenClinic Grosshansdorf, Hospital Universitario Insular de Gran Canaria, Kingston General Hospital, Westmead Hospital, The University of Sydney +12 more
Cites: 54
Cited by: 8,798
Related to: 10
FWCI: 453.3
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze